Our Investment Focus & Portfolio

Investments in other technologies incl. Microbiome and Infectious Diseases

Aelin Therapeutics
Eyevensys S.A.S.
Topas Therapeutics

Aelin Therapeutics

Aelin Therapeutics

The company pioneers a novel modality in drug development to develop a complete new class of antibiotics and first in class therapeutics against high value typical undruggable human targets. The technology, branded Pept-insTM, harnesses the power of protein aggregation to specifically induce a functional knockdown of a target protein. Aelin Therapeutics was founded by VIB and its partner universities KU Leuven, VUB, UGent, based on the ground-breaking work of renowned structural biologists Prof Joost Schymkowitz and Prof Frederic Rousseau. Aelin Therapeutics raised €27 million in a Series A financing round in December 2017 with a strong investor syndicate including LSP (the Netherlands), PMV (Belgium), Novartis Venture Fund (Switzerland), Boehringer Ingelheim Venture Fund (Germany) and Fund+ (Belgium).

Year of investment: 2017; BIVF Board Representative: Frank Kalkbrenner
www.aelintx.com

Eyevensys S.A.S.

Eyevensys S.A.S.

Eyevensys S.A.S. is a developer of a new non-viral gene therapy process to treat ocular illnesses. The new process enables prolonged production of therapeutic proteins through injection and electrotransfer of expression plasmids into the ciliar muscle and is aimed at treating uveitis and AMD. In stage two, Eyevensys will focus on treating more common conditions such as diabetic retinopathy.The company was founded in Paris (France) in 2009 by Francine Behar-Cohen, professor of medicine at Paris Descartes University, head of ophthalmology at l'Hotel Dieu.

Year of investment: 2013; BIVF Board Representative: Johannes Zanzinger
www.eyevensys.com

Topas Therapeutics

Topas Therapeutics

Topas Therapeutics is a private Hamburg-based biotechnology company focused on developing peptide-loaded nanoparticles to address immuno-tolerization of major unmet clinical need, including autoimmune diseases, allergies and anti-drug antibodies. Topas’ technology platform induces antigen-specific immune tolerance by harnessing the liver’s natural immuno-tolerizing capabilities.

Year of investment: 2017; BIVF Board Representative: Sebastian Kreuz
www.topas-therapeutics.com/topas/home/